Please login to the form below

Not currently logged in
Email:
Password:

Valeant appoints company group chairman

Ari Kellen joins from McKinsey & Company

Fast-growing Canadian pharma company Valeant Pharmaceuticals has appointed Dr Ari Kellen as executive VP and company group chairman.

Dr Kellen joins from McKinsey & Company where he was a senior partner at the consultancy firm's mid-Atlantic office.

He spent 22 years at McKinsey leading a number of a studies for healthcare companies, including corporate strategies for boards and top management teams, business unit strategies for medical device, pharma and biotech, and health care services clients, and regional and country growth strategies.

J Michael Pearson, chairman and CEO of Valeant, said: "Ari's broad experience in developing comprehensive growth strategies for healthcare companies will be invaluable to us as we continue to expand our successful growth trends.

“After having worked with Ari for many years, I know that not only will he fit in well with the rest of the team, but he will be a strong advocate for the long-term shareholder focused culture at Valeant."

28th November 2013

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Fendix

Latest intelligence

World Diabetes Day: Interaction and impact of diabetes on mental health
For World Diabetes Day on the 14th November 2018, Nisha Shahrukh - Medical Writer at Mednet Group has written an article depicting the impact diabetes has on mental health. Including...
EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think
Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...

Infographics